Celularity (CELU) vs Serina Therapeutics (SER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Celularity (CELU) has outperformed Serina Therapeutics (SER) over the past year, losing 32.1% versus a loss of 64.2%. Over five years, SER leads with a -93.9% price change compared with -98.0% for CELU. Serina Therapeutics is the larger company by market cap ($50.8 million vs $50.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELU | SER |
|---|---|---|
| Share price | $1.56 | $2.00 |
| Market cap | $50.62M | $50.80M |
| 1-day change | +6.85% | -0.50% |
| YTD return | +31.53% | +4.55% |
| 1-year return | -32.09% | -64.16% |
| 5-year return | -97.97% | -93.91% |
| EPS (TTM) | $-2.73 | $-1.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.55 | $5.60 |
| 52-week low | $0.56 | $1.22 |
| Distance from 52-week high | -38.82% | -64.29% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +375.00% |
| Average volume | 3.89M | 63.89K |
| Shares outstanding | 32.45M | 25.40M |
| Employees | 115 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CELU has outperformed SER by 32.1 percentage points over the past year.
About Celularity
CELU stock →Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees
About Serina Therapeutics
SER stock →Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
CELU vs SER FAQ
Which is bigger, Celularity or Serina Therapeutics?
Serina Therapeutics (SER) is larger, with a market capitalization of $50.80M compared with $50.62M for Celularity (CELU).
Which stock has performed better over the past year, CELU or SER?
CELU returned -32.09% over the past 12 months, compared with -64.16% for SER (price return, excluding dividends). Past performance does not predict future results.
Are Celularity and Serina Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.